Tofogliflozin: A highly selective sglt2 inhibitor for the treatment of type 2 diabetes

Drugs of Today

Volumn 50, Issue 11, 2014, Pages 739-745

  Rosenwasser, R F ^a   Rosenwasser, J N ^b   Sutton, D ^c   Choksi, R ^a   Epstein, B ^a  

^a East Coast Institute for Research   (United States)

^b AMERICAN UNIVERSITY   (United States)

^c Northeast Florida Endocrine and Diabetes Associates   (United States)

Author keywords

Diabetes; Sodium glucose cotransporter 2; Tofogliflozin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PHLORIZIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE; TOFOGLIFLOZIN; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

DIABETIC PATIENT; DIET THERAPY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; JAPANESE (PEOPLE); KETONURIA; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHARMACOPHORE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POLLAKISURIA; REVIEW; SYSTEMATIC REVIEW; URINARY EXCRETION; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VOLUME OF DISTRIBUTION AT STEADY-STATE; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT;

ANIMALS; BENZHYDRYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84918523582     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.11.2232267     Document Type: Review

References (24)

1. Diabetes: Fact Sheet No.312. World Health Organization: Geneva, 2011: http://www.who.int/features/factfiles/diabetes/facts/en/
2. Stark Casagrande, S., Fradkin, J.E., Saydah, S.H., Rust, K.F., Cowie, C.C. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013, 36(8): 2271-9
3. DeFronzo, R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58(4): 773-95
4. Wright, E.M., Loo, D.D., Hirayama, B.A. Biology of human sodium glucose transporters. Physiol Rev 2011, 91(2): 733-94
5. DeFronzo, R.A., Davidson, J.A., Del Prato, S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012, 14(1): 5-14
6. Magen, D., Sprecher, E., Zelikovic, I., Skorecki, K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 2005, 67(1): 34-41
7. Suzuki, M., Honda, K., Fukazawa, M. et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporters 2 inhibitor, improves glycemic control in diabetic rates and mice. J Pharmacol Exp Ther 2012, 341(3): 692-701
8. Santer, R., Kinner, M., Lassen, C.L. et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003, 14(11): 2873-82
9. Ehrenkranz, J.R., Lewis, N.G., Kahn, C.R., Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005, 21(1): 31-8
10. Ohtake, Y., Sato, T., Kobayashi, T. et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012, 55(17): 7828-40
11. Discontinuation of the development of Remogliflozin by GlaxoSmithKline [news Release]. Kissei Pharmaceutical Co., Ltd., July 3, 2009
12. Tanizawa, Y., Kaku, K., Araki, E. et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014, 15(6): 749-66
13. Roche returns development and marketing rights of SGLT2 inhibitor CSG452 to Chugai [news release]. Chugai Pharmaceutical Co., Ltd., July 5, 2011
14. License agreement of SGLT2 inhibitor CSG452 in Japan [news release]. Chugai Pharmaceutical Co., Ltd., October 26, 2012
15. Zell, M., Husser, C., Kuhlmann, O. et al. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica 2014, 44(4): 369-78
16. Schwab, D., Portron, A., Backholer, Z., Lausecker, B., Kawashima, K. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet 2013, 52(6): 463-73
17. Schwab, D., Portron, A., Fukushima, Y., Backholer, Z., Kuhlmann, O., Saito, T., Ikeda, S. Tofogliflozin a selective SGLT2 inhibitor exhibits highly favourable drug properties for use in patients with renal impairment and for combination with other medicines. 48th Annu Meet Eur Assoc Study Diabetes (EASD) (October 1-5, Berlin) 2012, Abst 767
18. Effect of renal impairment on pharmacodynamics and pharmacokinetics of RO4998452: A multiple-center, open-label, parallel group study following single oral dosing of RO4998452 to type 2 diabetes patients with varying degrees of renal impairment (NCT00933972). ClinicalTrials.gov Web site. Accessed September 7, 2014
19. A multi-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/tolerability and pharmacokinetics of five dose levels of RO4998452 in patients with type 2 diabetes mellitus (NCT00800176). ClinicalTrials.gov Web site. Accessed September 7, 2014
20. Kadowaki, T., Ikeda, S., Takano, Y. et al. Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone. 72nd Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 8-12, Philadelphia) 2012, Abst 80-OR.
21. Kaku, K., Watada, H., Iwamoto, Y. et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporters-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014, 28; 13: 65
22. Araki, E., Kaku, K., Watada, H., Iwamoto, Y., Utsunomiya, K., Terauchi, Y., Tobe, K, Tanizawa, Y. Verification of the efficacy and safety of tofogliflozin, a novel SGLT2 inhibitor, in Japanese patients with type 2 diabetes mellitus: results from a phase 2/3 clinical study. 49th Annu Meet Eur Assoc Study Diabetes (EASD) (September 23-27, Barcelona) 2013, Abst 929
23. Tanizawa, Y., Araki, E., Tobe, K., Terauchi, Y., Utsunomiya, K., Iwamoto, Y., Watada, H., Kaku, K. Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycaemic agents in Japanese patients with type 2 diabetes. 49th Annu Meet Eur Assoc Study Diabetes (EASD) (September 23-27, Barcelona) 2013, Abst 185
24. A randomized, double blind placebo controlled 2-arm parallel group, multicenter study with a 16-week treatment assessing the efficacy and safety, and 52-week long term safety including 36-week open label extension of tofogliflozin with insulin treatment in type 2 diabetes mellitus (NCT02201004). ClinicalTrials.gov Web site. Accessed September 7, 2014